ArticleNature communications2025
Engineering the auxin-inducible degron system for tunable in vivo control of organismal physiology.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Getting nuclear size just right - emerging mechanisms regulating nuclear scaling and morphology.Journal of cell science · 2026Review
- Autophagy: A Double-Edged Sword in the Aging ofInternational journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The auxin-inducible degron (AID) system is designed for the rapid and near-complete degradation of a specific target protein in vivo. However, to understand the dynamics of complex physiological networks, researchers often need methods that produce graded, quantitative changes in degradation rates for multiple proteins simultaneously. Here, we develop the AID system for in vivo, quantitative control over the abundance of multiple proteins simultaneously. First, by measuring and modeling the on- and off-target activities of different AID system variants in Caenorhabditis elegans, we characterize a variant of the E3 ubiquitin ligase subunit TIR1, which provides improved degradation activity compared to the original AID and AID2 systems. Then, we develop a TIR1 expression construct that enables simultaneous pan-somatic and germline protein degradation. Finally, we expand the AID toolkit to allow independent, simultaneous degradation of two distinct tissue-specific proteins. Together, these technologies enable new in vivo approaches for studying quantitative cellular biology and organismal dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.